scispace - formally typeset
A

Alan M. Garber

Researcher at Harvard University

Publications -  298
Citations -  16901

Alan M. Garber is an academic researcher from Harvard University. The author has contributed to research in topics: Health care & Cost effectiveness. The author has an hindex of 69, co-authored 298 publications receiving 16297 citations. Previous affiliations of Alan M. Garber include VA Palo Alto Healthcare System & Baylor College of Medicine.

Papers
More filters
Journal ArticleDOI

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

TL;DR: Liraglutide is safe and effective as initial pharmacological therapy for type 2 diabetes mellitus and leads to greater reductions in HbA(1c), weight, hypoglycaemia, and blood pressure than does glimepiride.
Journal ArticleDOI

Economic Foundations of Cost-Effectiveness Analysis

TL;DR: It is shown how a cost-effectiveness criterion can be derived to guide resource allocation decisions, and how it varies with age, gender, income level, and risk aversion.
Journal ArticleDOI

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.

TL;DR: In this article, the authors compared the safety and efficacy of low-molecular-weight heparins with those of unfractionated heparin for treatment of acute deep venous thrombosis.
Journal ArticleDOI

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

TL;DR: In subjects with type 2 diabetes poorly controlled on OADs, initiating insulin therapy with twice-daily BIAsp 70/30 was more effective in achieving HbA(1c) targets than once-daily glargine, especially in subjects with Hb a( 1c) >8.5%.